The primary goal of the Developmental Core of the Harvard University CFAR is to promote basic, clinical, behavioral and translational HIV/AIDS research activities at Harvard University. The Developmental Core provides the infrastructure through which short-term research proposals from individual and collaborating investigators are solicited, reviewed, and funded. The Developmental Core also promotes HIV research collaboration across Harvard University, and facilitates the development of new experimental approaches in high priority areas. Through funding of Scholar awards and prioritizing funding of investigators without prior R01-type funding, the Developmental Core fosters career development of junior HIV researchers. Dr. Johnson will serve as the Director of the Developmental Core, working in concert with the Associate Director, Dr. Shahin Lockman (HSPH, BWH) and the HU CFAR Administrative Staff.

Public Health Relevance

The overarching goal of the Developmental Core is to further the research priorities of the HU CFAR as outlined by the research agendas of the Scientific Programs by helping to develop and promote multidisciplinary research in the prevention, detection, and treatment of HIV/AIDS in areas of basic, clinical, epidemiological, behavioral, and translational research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI060354-10
Application #
8523741
Study Section
Special Emphasis Panel (ZAI1-SV-A)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
10
Fiscal Year
2013
Total Cost
$703,521
Indirect Cost
$50,601
Name
Harvard University
Department
Type
DUNS #
082359691
City
Cambridge
State
MA
Country
United States
Zip Code
02138
Ballandras-Colas, Allison; Brown, Monica; Cook, Nicola J et al. (2016) Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function. Nature 530:358-61
Jain, Sachin; Oldenburg, Catherine E; Mimiaga, Matthew J et al. (2016) High Levels of Concomitant Behavioral Health Disorders Among Patients Presenting for HIV Non-occupational Post-exposure Prophylaxis at a Boston Community Health Center Between 1997 and 2013. AIDS Behav 20:1556-63
Sunshine, Sara; Kirchner, Rory; Amr, Sami S et al. (2016) HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol 90:4511-9
Krakower, Douglas S; Mayer, Kenneth H (2016) Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough? J Infect Dis 214:983-5
Mayer, Kenneth H; Krakower, Douglas S; Boswell, Stephen L (2016) Antiretroviral Preexposure Prophylaxis: Opportunities and Challenges for Primary Care Physicians. JAMA 315:867-8
Saito, Akatsuki; Henning, Matthew S; Serrao, Erik et al. (2016) Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo. J Virol 90:6918-35
Krakower, Douglas S; Maloney, Kevin M; Grasso, Chris et al. (2016) Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. J Int AIDS Soc 19:21165
Brown, Carolyn A; Suneja, Gita; Tapela, Neo et al. (2016) Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist 21:731-8
McDavitt, Bryce; Bogart, Laura M; Mutchler, Matt G et al. (2016) Dissemination as Dialogue: Building Trust and Sharing Research Findings Through Community Engagement. Prev Chronic Dis 13:E38
Gandhi, Rajesh T; Kwon, Douglas S; Macklin, Eric A et al. (2016) Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 71:246-53

Showing the most recent 10 out of 844 publications